2022 Fiscal Year Final Research Report
Development of novel treatment targeting S1P signaling on psoriasis in mice model
Project/Area Number |
20K17344
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 53050:Dermatology-related
|
Research Institution | Kanazawa University |
Principal Investigator |
Kano Miyu 金沢大学, 医学系, 協力研究員 (60756237)
|
Project Period (FY) |
2020-04-01 – 2023-03-31
|
Keywords | 乾癬 / スフィンゴシン1リン酸 / S1P1受容体 |
Outline of Final Research Achievements |
Sphingosine-1-phosphate (S1P) / S1P receptor signal regulates activated T-cell accessing inflamed tissues and modulates lymphocyte differentiation and inhibits keratinocyte proliferation, differentiation and migration. In mice model of psoriasis, administration of a novel selective S1P1 receptor inhibitor improved epidermal hyperkeratosis and reduced inflammatory cell infiltration into the skin. Furthermore, an increase in the number of regulatory T cells in the spleen was observed. S1P1 receptor inhibitors attenuate mRNA expression of inflammatory cytokines in the skin, such as IL-17 and IL-23. These results suggest the therapeutic efficacy of selective S1P1 receptor inhibitors in the treatment of psoriasis.
|
Free Research Field |
皮膚科学
|
Academic Significance and Societal Importance of the Research Achievements |
乾癬は全身に紅色局面を形成し、表皮の細胞増殖亢進と分化不全を特徴とする自己免疫性炎症性皮膚疾患である。また長期にわたって寛解と増悪を繰り返す慢性疾患である。本研究では新規選択的S1P1受容体阻害剤をイミキモド誘発乾癬モデルマウスに投与したところ、皮膚症状の改善を認め、乾癬に対する有効な治療薬となる可能性が示唆された。この結果は、乾癬におけるS1P/S1P受容体シグナルを標的とした新規治療法の開発につながる重要な発見であり、学術的意義があると考えられる。
|